Research Article
TAK-242 Ameliorates Hepatic Fibrosis by Regulating the Liver-Gut Axis

Sujie Liu,1 Juan Wu,2 Pingping Chen,2 Shadi A. D. Mohammed,2 Jingbo Zhang,1 and Shumin Liu2

1Graduate School of Heilongjiang University of Chinese Medicine, Harbin, 150040 Heilongjiang, China
2Institute of Traditional Chinese Medicine, Heilongjiang University of Chinese Medicine, Harbin, 150040 Heilongjiang, China

Correspondence should be addressed to Shumin Liu; keji-liu@163.com

Received 6 June 2022; Revised 15 July 2022; Accepted 25 July 2022; Published 16 August 2022

Academic Editor: Syed Sameer Aga

Copyright © 2022 Sujie Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. The aims of this study were to investigate the impact of TAK-242 on the Toll-like receptor 4 (TLR4)/myeloid differentiation factor 88 (MyD88)/nuclear transcription factor-κB (NF-κB) signal transduction pathway in rats with hepatic fibrosis (HF) using the liver gut axis and to investigate the molecular mechanism of its intervention on HF.

Methods. SPF grade SD male rats were randomly allocated to the control, model, and TAK-242 groups. For 8 weeks, the model and TAK-242 groups received 3 mL·kg⁻¹ (the initial dose 5 mL·kg⁻¹) intraperitoneal injections of 40% CCL₄ olive oil solution. TAK-242 (5 mg·kg⁻¹) was administered once a day for 5 days after modeling. The pathological alterations of liver and small intestine tissues in each group were observed using H&E and Masson staining. ELISA was used to measure serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), direct bilirubin (DBIL), total bilirubin (TBIL), interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-α). RT-qPCR was utilized to identify the mRNA expression level of IL-1β, IL-6, TNF-α, TLR4, MyD88, and NF-κB in rat liver and small intestine tissues. The protein level of IL-1β, IL-6, TNF-α, TLR4, MyD88, and NF-κB protein in rat liver and small intestine tissues was determined utilizing Western blot and IHC.

Results. TAK-242 significantly reduced AST, ALT, TBIL, and DBIL expression in HF rats’ serum (P < 0.01) and alleviated liver tissue injury. Hematoxylin-eosin (H&E) and Masson staining revealed inflammatory cell infiltration and fibrous proliferation in the liver and small intestine tissue in the model group and partial cell swelling in the TAK-242 group, which indicated a considerable improvement compared to the model group. RT-qPCR, Western blot, and IHC data indicated that TAK-242 reduced the IL-1β, IL-6, TNF-α, TLR4, MyD88, and NF-κB expression in the liver and small intestine tissues of HF rats.

Conclusion. TAK-242 might downregulate the TLR4/MyD88/NF-κB signal pathway through the liver-gut axis, suppress the inflammatory response, and eventually alleviate HF in rats.

1. Introduction

Hepatic fibrosis (HF) is a wound healing process induced by chemical toxic damage, chronic hepatitis virus infection, autoimmune liver disease, alcoholism, and other variables that result in aberrant production and deposition of liver extracellular matrix. [1] Clinically, even once the cause is eliminated, HF persists and may progress to cirrhosis, hepatocellular cancer, and, eventually, liver failure leading to death [2]. In contrast to irreversible cirrhosis, a growing number of investigations have shown that HF is a dynamical and probably bilateral process with an intrinsic possibility for recovery and remodeling [3, 4], providing many new ideas for anti-HF mechanism research and clinical treatment. Multiple studies have revealed that the liver-gut axis is usually linked to the advancement of liver disease [5, 6]. The intestinal mucosal barrier function is weakened when intestinal homeostasis is disrupted, resulting in a large influx of intestinal endotoxins into the liver via the portal system [7]. These bacterial products aggravate the development of fibrotic lesions in liver tissue by stimulating natural immune receptors, such as Toll-like receptors (TLRs). It activates myeloid differentiation factor 88 (MyD88) to release serine-threonine protein 1 kinase (IRAK 1 kinase)
[8], which ultimately leads to the entry of nuclear transcription factor-kB (NF-kB) into the nucleus and ultimately activates downstream pathways involved in liver inflammation and fibrogenesis [5, 9]. It induces apoptosis in hepatic macrophages and the production of inflammatory molecules such as interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-α) [10–12], which exacerbate and destroy the intestinal barrier.

TAK-242 (Figure 1) is a small molecule of a toll-like receptor 4 (TLR4) that suppresses TLR4 activation by interacting directly with the intracellular domain of TIR [13]. Furthermore, TAK-242 shows hepatoprotective effects on Lipopolysaccharide/D-galactose (LPS/D-GalN)-induced fulminant hepatitis in mice [14], as well as suppression of TLR4 signaling to alleviate acute and chronic acute liver failure in animals. The TAK-242 has been demonstrated to minimize target organ damage and systemic inflammation in animal models [11], as well as ischemia/reperfusion injury in transplanted livers [15]; however, it is unclear if TAK-242 can specifically protect rats from HF through the liver-gut axis effects. This study evaluated the effect of TAK-242, a potential anti-inflammatory drug, in a CCl4-induced HF rat model, revealed its mechanism of action, and identified a potential therapeutic target for clinical HF therapy.

2. Materials and Methods

2.1. Animals and Experimental Protocol. SD male rats (SPF grade), weighing 230 ± 10 g (10 weeks old), were supplied by Heilongjiang University of Traditional Chinese Medicine's Experimental Animal Center (animal certificate number: SYXK (black) 2018-007). The rats were kept in the germ-free environment downstream pathways involved in liver inflammation and fibrogenesis [5, 9]. It induces apoptosis in hepatic macrophages and the production of inflammatory molecules such as interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-α) [10–12], which exacerbate and destroy the intestinal barrier.

TAK-242 (Figure 1) is a small molecule of a toll-like receptor 4 (TLR4) that suppresses TLR4 activation by interacting directly with the intracellular domain of TIR [13]. Furthermore, TAK-242 shows hepatoprotective effects on Lipopolysaccharide/D-galactose (LPS/D-GalN)-induced fulminant hepatitis in mice [14], as well as suppression of TLR4 signaling to alleviate acute and chronic acute liver failure in animals. The TAK-242 has been demonstrated to minimize target organ damage and systemic inflammation in animal models [11], as well as ischemia/reperfusion injury in transplanted livers [15]; however, it is unclear if TAK-242 can specifically protect rats from HF through the liver-gut axis effects. This study evaluated the effect of TAK-242, a potential anti-inflammatory drug, in a CCl4-induced HF rat model, revealed its mechanism of action, and identified a potential therapeutic target for clinical HF therapy.

2.2. Sample Preparation. The rats were anesthetized with a 3% pentobarbital sodium solution. Blood was taken from the abdominal aorta and centrifuged for 15 minutes at 3500 r/min. The serum was isolated and refrigerated at -80°C for analysis. The liver and small intestine tissues were separated, the left two lobes of the liver and a part of the small intestine tissue were preserved with 4% paraformalde-
after being treated with a pH 6.0 sodium citrate buffer solution. Then, add TLR4 (ab22048, Abcam), MyD88 (ab133739, Abcam), NF-κB (ab32536, Abcam), IL-6 (ab208113, Abcam), IL-1β (66737-1-lg, Proteintech), TNF-α (ab1793, Abcam), ZO-1 (66452-1-lg, Proteintech), and Claudin-1 (ab208113, Abcam) were stained for target proteins. DAB was observed and photographed under a microscope (motic, DMB5-2231P1 type) after dark color development. The brown color was positive. Image-Pro Plus 6.0 software was utilized for processing, and the integrated absorbance IA/area was used as the semiquantitative result of the detection index.

2.7. Western Blot Analysis. Liver or small intestine samples were ground and mixed with 1 mL of total protein extract to homogenize before centrifugation at 9000 rpm for 10 minutes to assess protein concentration. After boiling the protein for 3 minutes to denature it, the samples were put in a specified sequence for electrophoresis. When the bromophenol blue migrated to the bottom 0.5 cm of the separation gel, the gel glass plate was removed, and the polyvinylidene fluoride (PVDF) membrane was transferred. The electrophoresis was completed. After that, the electrotransfer membrane was blocked with 5% nonfat dry milk (PBS). At 4°C overnight, primary antibodies TLR4 (Ptgcn, 19811-1-AP), NF-κB p65 (Ptgcn, 10745-1-AP), MyD88 (Ptgcn, 23230-1-AP), IL-1β (CST, #12242), IL-6 (CST, #12912), TNF-α (Ptgcn, 60291-1-lg), and β-actin (Ptgcn, 66009-1-lg) were mixed with 1 mL of enzyme-labeled secondary antibody. After washing the membrane with 2-3 mL of PBST, develop it with ECL reagent and assess the gray value of each band using Image-Pro Plus 6.0 software. The relative protein expression is determined by the ratio of the target protein band to β-actin.

2.8. Statistical Analysis. GraphPad Prism 8.0 was utilized for the analysis. The experimental data were presented as the mean ± standard deviation (x ± s), and they were tested for normality and variance homogeneity. When comparing two samples, the t-test was used, and when comparing multiple groups, one-way ANOVA was used. P < 0.05 indicating a statistically significant difference.

3. Results

3.1. TAK-242 Effect of Reducing HF in HF Rats. The hepatocytes of the rats in the control group were neatly arranged, with a clear structure, no degeneration or necrosis, no congestion in the hepatic sinus, and also no inflammatory cell infiltrate or fibrotic tissue proliferation, while in the model group, a considerable number of foam cells were found in the tissue of the rats and infiltration with a small number of lymphocytes and hyperplasia of connective tissue around a large number of venous vessels, accompanied by punctate necrosis of hepatocytes, nuclear fragmentation or lysis, enhanced eosinophilic cytoplasm, and rare bile duct hyperplasia. The TAK-242 group’s liver tissue structure improved to varying degrees, connective tissue hyperplasia was greatly decreased, and the fibrous septum was significantly reduced, as shown in Figure 2. Furthermore, serum levels of AST, ALT, DBIL, and TBIL in the model group were significantly higher than in the control group (P < 0.01). The levels of AST, ALT, DBIL, and TBIL in serum of the TAK-242 group were significantly lower (P < 0.01) than those of the model group. The findings demonstrated that the CCL4-induced rat hepatic fibrosis model was effectively created.

3.2. TAK-242 Effect on Liver Inflammation in HF Rats. HF upregulates inflammatory factors such as IL-1β, IL-6, and TNF-α in the liver. Compared to the control group, the model group had significantly higher levels of IL-1β, IL-6, and TNF-α secretion and expression. In comparison to the model group, the TAK-242 group significantly reduced serum levels of IL-1β, IL-6, and TNF-α. Meanwhile, the protein and mRNA expressions of IL-1β, IL-6, and TNF-α were significantly lower in the TAK-242 group’s liver tissue, Figures 3(a)–3(h). These findings suggested that TAK-242 might reduce the inflammatory response in HF rats.

3.3. TAK-242 Effect in Intestinal Barrier Function of HF Rats. Claudin-1 and ZO-1 are two typical tight junction proteins that play important roles in the intestinal epithelium’s tight junctions and permeability. The small intestine tissue cells in the control group’s rats were well arranged, and there were no aberrant intestinal villi or cell infiltration. The mucosal layer of the small intestine tissue of the model group rats revealed a lot of epithelial edema, loose cytoplasm, and light staining, with dispersed lymphocyte infiltration, and a minor quantity of the epithelium was necrotic and shed, with condensed and stained nuclei. There were multiple mucosal layers and moderate edema of intestinal villi in the TAK-242 group’s intestinal tissue, and the epithelium was separated from the lamina propria. The small intestine tissue of the TAK-242 group was improved to
varying degrees as compared to the model group, and intestinal villus edema and lymphatic infiltration were dramatically reduced, Figure 4(a). In terms of mRNA and protein levels, claudin-1 and ZO-1 in the model group were significantly lower than those in the control group. In contrast, claudin-1 and ZO-1 in the TAK-242 group were significantly lower than in the model group (Figures 4(d) and 4(e)).

3.4. TAK-242 Can Reduce Intestinal Inflammation in HF Rats. When the intestinal epithelium’s tight junctions and permeability are destroyed, the mucosal barrier function of the intestinal barrier is weakened, resulting in an inflammatory reaction in the intestinal tract that acts on the liver via the portal venous system and aggravates the pathological changes in the liver tissue. The expressions of IL-1β, IL-6, and TNF-α in the intestinal wall were measured to assess the influence of HF on the intestine. The mRNA and protein levels of IL-1β, IL-6, and TNF-α in the intestinal wall were increased significantly in the model group compared to the control group, while the secretion and expression levels of IL-1β, IL-6, and TNF-α in the TAK-242 group were significantly decreased compared with those in the model group (Figures 5(a)–5(e)). These results indicate that TAK-242 may reduce intestinal inflammation caused by hepatic fibrosis.
3.5. Effects of TAK-242 on TLR4 Signaling Pathway Expression in HF Rats. TLR4 is the initial barrier to bacterial detection in the gut and is a key component of gut innate immunity. It functions as an immunological recognition receptor on the cell surface as well as an intracellular transmembrane signaling protein. The MyD88-dependent signaling pathway dominates the signal transduction process following TLR4 activation. By simultaneously activating different intracellular signal adaptor molecules, NF-κB downstream of the pathway is eventually activated to control the production of numerous inflammatory mediators. As a result, we identified key proteins associated with the TLR4 signaling pathway in the liver and small intestine tissue, respectively. The findings demonstrated that the model group had significantly greater TLR4, NF-κB, and MyD88 secretion and expression levels than the control group. TLR4, NF-κB, and MyD88 secretion and expression levels in the TAK-242 group were significantly lower than those in the model group, Figures 6(a)–6(j).

Figure 3: TAK-242 alleviated liver inflammation in HF rats. (a) IHC-stained liver sections (magnification ×200). (b) Chromogenic intensity of proinflammatory cytokines. (c) RT-qPCR detection of hepatic proinflammatory cytokine expression level. (d, e) Western blot detection of hepatic proinflammatory cytokine protein expression. (f) Serum IL-1β (ng/mL). (g) Serum IL-6 (ng/mL). (h) Serum TNF-α (ng/mL). n = 8. Compared with the control group, \( * P < 0.01 \); compared with model group, \( * P < 0.05 \) and \( ** P < 0.01 \). (f–h) Green, control; red, model; blue, TAK-242.
4. Discussion

The principal manifestation of liver fibrosis is an abnormal accumulation of extracellular matrix (ECM), which is typically regarded as an intermediate stage that may be cured or progress to cirrhosis and end-stage liver disease [28]. According to epidemiological data, more than one million individuals worldwide die from cirrhosis each year [29]. Cirrhosis is responsible for 9.2 fatalities per 100,000 people in the United States, according to epidemiological statistics from 2017 [30]. The burden of liver fibrosis raises not only the morbidity and mortality of end-stage liver disease but also the risk of extrahepatic disease. Modern research has established that the liver and the gut are not only physiologically connected not only in terms of structure (enterohepatic circulation) but also in terms of physiological functioning [31]. The findings of this investigation revealed that TAK-242 might inhibit the TLR4/MyD88/NF-κB signaling pathway through the liver-gut axis, hence curing HF.

Researchers have found that [32–34] ALT and AST are essential enzymes in the liver, and their levels are directly associated to the progression of liver fibrosis and inflammation, and when liver cells are injured, enzymes enter the bloodstream via the cells, and the function of the liver cells

![Figure 4: TAK-242 can regulate intestinal barrier function in HF rats. (a) Hematoxylin-eosin (H&E) staining of liver tissue, Masson staining (magnification, ×200). (b) IHC stained liver sections (magnification ×200). (c) Color intensity of intestinal wall permeability. (d, e) Western blot detection of intestinal wall tight junction protein expression. n = 8. Compared with the control group, **P < 0.01; compared with the model group, *P < 0.05 and **P < 0.01.](image_url)
to convert bilirubin is compromised. Inflammation in liver tissue destroys the capillary bile duct and impairs direct bilirubin excretion, resulting in elevated AST, ALT, TBIL, and DBIL levels. Our findings also revealed that serum AST, ALT, TBIL, and DBIL levels were greater in the model group than in the control group and that serum AST, ALT, TBIL, and DBIL levels could be significantly lowered following TAK-242 intervention. According to the pathological alterations in liver tissue, the model group had a high number of connective tissue and fibrous tissue hyperplasia and inflammatory cell infiltration, while the TAK-242 group’s liver tissue improved to varied degrees. This result suggests...
Figure 6: Continued.
that TAK-242 may alleviate the HF damage induced by CCl₄.

Liu et al. [35] observed that bacterial translocation and elevated lipopolysaccharide levels in the gut stimulate TLR4 signaling and HSC activation in the liver. Meanwhile, claudins and occludins tight junctions play a vital role in the creation and maintenance of the intestinal epithelial barrier’s integrity [36–38]. In our study, the intestinal mucosa tissues of HF rats in the model group were damaged, intestinal villi were diminished, and a considerable number of inflammatory cells were identified in the intestinal mucosa. Protein levels in the intestinal mucosa and villus were dramatically reduced after TAK-242 therapy. TAK-242 dramatically enhanced the protein levels of claudin-1 and ZO-1 in the small intestine of rats. TAK-242’s antifibrosis activity in HF rats was suggested to be directly related to intestinal function.

In recent years, researchers have shown that inflammation is a major factor in the progression of liver fibrosis [39]. Liver injury may retain the active surface of HSCs and accelerate the migration of inflammatory cells to the injured liver, secreting a significant number of inflammatory mediators such as TNF-α, IL-6, and IL-1β to enhance the development of liver fibrosis [10–12, 40, 41]. TAK-242 was
also observed to reduce the incidence of liver inflammation and fibrosis in Hu et al.’s research [42]. Similarly, the current research found that TAK-242 lowered the levels of inflammatory factors IL-1β, IL-6, and TNF-α in the liver. Furthermore, following TAK-242 treatment, the contents of inflammatory components in the small intestine of rats reduced, indicating that control of TLR4 expression may not only suppress the inflammatory response in the liver of HF rats. It also reduced the inflammatory response mediated by intestinal mucosal barrier damage in HF rats. These results revealed that TAK-242’s anti-HF action in rats was connected to improved liver inflammation through the liver-gut axis.

The TLR4 receptor is a pattern recognition receptor. Its primary ligands are PAMP (LPS and Gram-negative endotoxin) and DAMP, which include cell death products (mitotic nucleosomes, histones, and HMGB1) [43, 44]. The research by Wu et al. [45] revealed that this membrane receptor was expressed on a wide range of nonsubstantial and substantial cells, including hepatocytes and hepatic stellate cells. Following ligand binding, the receptor dimers and recruits adaptor molecules, such as TIR-domain adaptor protein (TIRAP) MyD88 and TRIF-associated adaptor molecule (TRAM) TRIF, to create intracellular signaling complexes [45, 46]. MyD88-dependent signaling activates NF-κB, while the TRIF-dependent pathway modulates interferon regulators, resulting in cytokine and interferon production [13]. Previous research by Naihua Hu et al. [47, 48] has demonstrated that TLR4/MyD88/NF-κB may have an anti-inflammatory and hepatoprotective effect by decreasing ECM accumulation and inflammatory factor expression. It was consistent with our findings that TLR4, MyD88, and NF-κB levels in HF rat liver tissue were elevated, whereas TLR4, MyD88, and NF-κB levels were dramatically lowered following TAK-242 therapy. TLR4 is the initial barrier to bacterial detection in the gut and is a key aspect of gut innate immunity. It functions as a cell surface immunological recognition receptor and an intracellular transmembrane signaling protein. Furthermore, TLR4, MyD88, and NF-κB levels in the small intestine of HF rats were significantly reduced after TAK-242 intervention, implying that TAK-242 improvement in HF rats may play a role by inhibiting the inflammatory response mediated by the TLR4/MyD88/NF-κB signaling pathway via the liver-gut axis.

Furthermore, changes in intestinal flora may help to explain the therapeutic mechanism; however, no research was conducted for this paper. As a result, the particular mechanism of TAK-242’s therapeutic action on HF through the liver-gut axis requires additional investigation. Nonetheless, there is no doubting that this research has demonstrated the critical function of TAK-242 in the management of hepatic fibrosis. Nonetheless, this study has described an important role for TAK-242 in the treatment of liver fibrosis. The creation process using CmapTools is shown in Figure 7 [49].
5. Conclusion

In summary, this research illustrates that TAK-242 is implicated in CCL4-induced HF and inflammatory factor release in HF rats. TAK-242’s anti-HF effect is most likely achieved by liver-gut axis suppression of inflammation through the TLR4/MyD88/NF-κB signaling pathway.

abbreviation

ALT: Alanine aminotransferase
AST: Aspartate aminotransferase
DBIL: Direct bilirubin
TBIL: Total bilirubin
IL-1β: Interleukin-1β
IL-6: Interleukin-6
TNF-α: Tumor necrosis factor alpha
TLR4: Toll-like receptor 4
MyD88: Myeloid differentiation factor 88
NF-κB: Nuclear factor kappa B
ZO-1: Membrane protein
Claudin-1: Transmembrane proteins.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors state that they have no conflicts of interest.

Authors’ Contributions

Sujie Liu, Juan Wu, and Shumin Liu conceived and designed the experiments. Sujie Liu analyzed the data. Sujie Liu, Shadi A.D. Mohammed, and Jingbo Zhang performed the experiments and wrote the manuscript. Pingping Chen provided valuable suggestions for the research. All the authors have read and approved the final manuscript.

Acknowledgments

This study was supported by the Natural Science Foundation of Heilongjiang Province (LH2020H099).

References

[1] S. Kataoka, A. Umemura, K. Okuda et al., “Honokiol acts as a potent anti-fibrotic agent in the liver through Inhibition of TGF-β1/SMAD signaling and autophagy in hepatic stellate cells,” International Journal of Molecular Sciences, vol. 22, no. 24, article 13354, 2021.
[2] N. Roehlen, E. Crouchet, and T. Baumert, “Liver fibrosis: mechanistic concepts and therapeutic perspectives,” Cells, vol. 9, no. 4, article 875, 2020.
[3] E. Hintermann and U. Christen, “The many roles of cell adhesion molecules in hepatic fibrosis,” Cells, vol. 8, no. 12, article 1503, 2019.
[4] H. Zheng, X. Wang, Y. Zhang, L. Chen, L. Hua, and W. Xu, “Pien-Tze-Huang ameliorates hepatic fibrosis via suppressing NF-κB pathway and promoting HSC apoptosis,” Journal of Ethnopharmacology, vol. 244, article 111856, 2019.
[5] O. Frasinariu, S. Ceccarelli, A. Alisi, E. Moraru, and V. Nobili, “Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies,” Digestive and Liver Disease, vol. 45, no. 7, pp. 543–551, 2013.
[6] M. Haderer, P. Neubert, E. Rinner et al., “Novel pathomechanism for spontaneous bacterial peritonitis: disruption of cell junctions by cellular and bacterial proteases,” Gastroenterology, vol. 71, no. 3, pp. 580–592, 2022.
[7] M. Matsuda and E. Seki, “Hepatic stellate cell-macrophage crosstalk in liver fibrosis and carcinogenesis,” Seminars in Liver Disease, vol. 40, no. 3, pp. 307–320, 2020.
[8] N. Yu, S. Hu, and Z. Hao, “Beneficial effect of stachydrine on the traumatic brain injury induced neurodegeneration by attenuating the expressions of Akt/mTOR/P13K and TLR4/NFκB pathway,” Translational Neuroscience, vol. 9, pp. 175–182, 2018.
[9] H. Hu, A. Lin, M. Kong et al., “Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives,” Journal of Gastroenterology, vol. 55, no. 2, pp. 142–158, 2020.
[10] P. Behzadi, H. A. García-Perdomo, and T. M. Karpiński, “Toll-like receptors: general molecular and structural biology,” Journal of Immunology Research, vol. 2021, 25 pages, 2022.
[11] P. Behzadi, A. S. Sameer, S. Nissar et al., “The interleukin-1 (IL-1) superfamily cytokines and their single nucleotide polymorphisms (SNPs),” Journal of Immunology Research, vol. 2022, 25 pages, 2022.
[12] A. S. Sameer and S. Nissar, “Toll-like receptors (TLRs): structure, functions, signaling, and role of their polymorphisms in colorectal cancer susceptibility,” BioMed Research International, vol. 2021, Article ID 1157023, 14 pages, 2021.
[13] N. Matsunaga, N. Tsuchimori, T. Matsumoto, and M. Ii, “TAK-242 (resatorvid), a small-molecule inhibitor of toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and its adaptor molecules,” Molecular Pharmacology, vol. 79, no. 1, pp. 34–41, 2011.
[14] H. Wang, X. Li, G. Dong et al., “Toll-like receptor 4 inhibitor TAK-242 improves fulminant hepatitis by regulating accumulation of myeloid-derived suppressor cell,” Inflammation, vol. 44, no. 2, pp. 671–681, 2021.
[15] Z. Shao, B. Jiao, T. Liu, Y. Cheng, H. Liu, and Y. Liu, “TAK-242 treatment ameliorates liver ischemia/reperfusion injury by inhibiting TLR4 signaling pathway in a swine model of Maastricht-category-III cardiac death,” Biomedicine & Pharmacotherapy, vol. 84, pp. 495–501, 2016.
[16] M. Hongyu and C. Hong, “Comparative study on pharmacological effects of Scutellaria baicalensis decoction and baicalin against liver fibrosis in rats,” World Chinese Medicine, vol. 13, no. 3, pp. 699–702, 2018.
[17] Z. Jingbo, C. Pingping, Y. Donghua et al., “Effects of radix scutellariae baikalensis and radix paonae rubra on liver fibrosis in rats,” Chinese Journal of Experimental Formulas of Chinese Medicine, vol. 28, no. 12, pp. 69–77, 2022.
[18] W. Haiyan, The effect and mechanism of TLR4 inhibitor TAK-242 on the pathogenesis of acute liver failure, Shandong University, China, 2021.
[19] S. Liu, S. Zhang, Y. Sun, and W. Zhou, “Transcriptomics changes in the peritoneum of mice with lipopolysaccharide-induced peritonitis,” International Journal of Molecular Sciences, vol. 22, no. 23, p. 13008, 2021.
[20] A. Shibata, K. Sugitza, Y. Furuta, Y. Mukimoto, O. Kamimura, and M. Akiyama, “Toll-like receptor 4 antagonist TAK-242 inhibits autoinflammatory symptoms in DITRA,” *Journal of Autoimmunity*, vol. 80, pp. 28–38, 2017.

[21] B. Liu, D. Wang, Y. Cao et al., “MitoTEMPO protects against podocyte injury by inhibiting NLRP3 inflammasome via PINK1/Parkin pathway-mediated mitophagy,” *European Journal of Pharmacology*, vol. 929, article 175136, 2022.

[22] R. Z. Pai, Q. Fang, G. Tian, B. Zhu, and X. Ge, “Expression and role of interleukin-1β and associated biomarkers in deep vein thrombosis,” *Experimental and Therapeutic Medicine*, vol. 22, no. 6, p. 1366, 2021.

[23] L. Feng, F. Huang, Y. Ma, and J. Tang, “The effect of high-fat diet and exercise intervention on the TNF-α level in rat spleen,” *Frontiers in Immunology*, vol. 12, article 671167, 2021.

[24] Q. Zeng, L. Ye, M. Ling et al., “TLR4/TRA6/NOX2 signaling pathway is involved in ventilation-induced lung injury via endoplasmic reticulum stress in murine model,” *International Immunopharmacology*, vol. 96, article 107774, 2021.

[25] S. Xu, Y. Wang, M. Yu et al., “LongoShengZhi capsule inhibits doxorubicin-induced heart failure by anti-oxidative stress,” *Biomedicine & Pharmacotherapy*, vol. 123, article 109803, 2020.

[26] M. Liguori, E. Digifico, A. Vacchini et al., “The soluble glycoprotein NMB (GP-NMB) produced by macrophages induces cancer stemness and metastasis via CD44 and IL-33,” *Cellular & Molecular Immunology*, vol. 18, no. 3, pp. 711–722, 2021.

[27] M. Gu, S. Zhang, Y. Zhao et al., “Cyclooxygenase incurs hepatic steatosis by activating farnesoid X receptor signalling,” *Pharmacological Research*, vol. 121, pp. 22–32, 2017.

[28] M. E. Zoubek, C. Trautwein, and P. Strnad, “Reversal of liver fibrosis: from fiction to reality,” *Best Practice & Research. Clinical Gastroenterology*, vol. 31, no. 2, pp. 129–141, 2017.

[29] E. A. Tsochatzis, J. Bosch, and A. K. Burroughs, “Liver cirrhosis,” *Lancet*, vol. 383, no. 9930, pp. 1749–1761, 2014.

[30] A. M. Moon, A. G. Singal, and E. B. Tapper, “Contemporary epidemiology of chronic liver disease and cirrhosis,” *Clinical Gastroenterology and Hepatology*, vol. 18, no. 12, pp. 2650–2666, 2020.

[31] L. Bartsch, M. P. S. Damasio, S. Subudhi, and H. K. Drescher, “Tissue-resident memory T cells in the liver: unique characteristics of local specialists,” *Cell*, vol. 99, no. 11, p. 2457, 2020.

[32] E. Giannini, R. Testa, and V. Savarino, “Liver enzyme alteration: a guide for clinicians,” *CMAJ: Canadian Medical Association journal = journal de l'Association medicale canadienne*, vol. 172, no. 3, pp. 367–379, 2005.

[33] M. Okuda, K. Li, M. R. Beard et al., “Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein,” *Gastroenterology*, vol. 122, no. 2, pp. 366–375, 2002.

[34] A. Hamoud, L. Weaver, D. E. Stec, and T. D. Hinds Jr., “Bilirubin in the liver-gut signaling axis,” *Trends in Endocrinology and Metabolism: TEM*, vol. 29, no. 3, pp. 140–150, 2018.

[35] Y. F. Liu, G. C. Niu, C. Y. Li et al., “Mechanism of ulcerative colitis-aggravated liver fibrosis: the activation of hepatic stellate cells and TLR4 signaling through gut-liver Axis,” *Frontiers in Physiology*, vol. 12, article 695019, 2021.

[36] R. E. Vandenbroucke, E. Dejonckheere, F. Van Hauwermeiren et al., “Matrix metalloproteinase 13 modulates intestinal epithelial barrier integrity in inflammatory diseases by activating TNF,” *EMBO Molecular Medicine*, vol. 5, no. 7, pp. 1000–1016, 2013.

[37] L. Zhang, Y. Wang, L. C. Tong et al., “Berberine alleviates dextran sodium sulfate-induced colitis by improving intestinal barrier function and reducing inflammation and oxidative stress,” *Experimental and Therapeutic Medicine*, vol. 13, no. 6, pp. 3374–3382, 2017.

[38] W. Wang, T. Xia, and X. Yu, “Wogonin suppresses inflammatory response and maintains intestinal barrier function via TLR4-MyD88-TAK1-mediated NF-κB pathway in vitro,” *Inflammation Research*, vol. 64, no. 6, pp. 423–431, 2015.

[39] H. J. Zhangdi, S. B. Su, F. Wang et al., “Crosstalk network among multiple inflammatory mediators in liver fibrosis,” *World Journal of Gastroenterology*, vol. 25, no. 33, pp. 4835–4849, 2019.

[40] A. Wree, T. M. Holtmann, M. E. Inzaugrart, and A. E. Feldstein, “Novel drivers of the inflammatory response in liver injury and fibrosis,” *Seminars in Liver Disease*, vol. 39, no. 3, pp. 275–282, 2019.

[41] S. Lemoine, A. Cadoret, H. el Mourabit, D. Thabut, and C. Housset, “Origins and functions of liver myofibroblasts,” *Biochimica et Biophysica Acta*, vol. 1832, no. 7, pp. 948–954, 2013.

[42] J. Hu, H. Du, Y. Yuan et al., “MFG-E8 knock-out aggravated nonalcoholic steatohepatitis by promoting the activation of TLR4/NF-κB signaling in mice,” *Mediators of Inflammation*, vol. 2022, Article ID 5791915, 13 pages, 2022.

[43] G. Paoliella, C. Mandato, L. Piatti, M. Poeta, M. Di Stasi, and P. Vajro, “Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease,” *World Journal of Gastroenterology*, vol. 20, no. 42, pp. 15518–15531, 2014.

[44] J. Wang, G. Z. He, Y. K. Wang, Q. K. Zhu, W. Chen, and T. Guo, “TLR4-HMGBl-, MyD88- and TRIF-dependent signaling in mouse intestinal ischemia/reperfusion injury,” *World Journal of Gastroenterology*, vol. 21, no. 27, pp. 8314–8325, 2015.

[45] C. Wu, C. Liu, K. Luo, Y. Li, J. Jiang, and F. Yan, “Changes in expression of the membrane receptors CD14, MHC-II, SR-A, and TLR4 in tissue-specific monocytes/macrophages following Porphyromonas gingivalis-LPS stimulation,” *Inflammation*, vol. 41, no. 2, pp. 418–431, 2018.

[46] M. Scott and T. Billiar, “β2-integrin-induced p38 MAPK activation is a key mediator in the CD14/TLR4/MD2-dependent uptake of lipopolysaccharide by hepatocytes,” *The Journal of Biological Chemistry*, vol. 283, no. 43, pp. 29433–29446, 2008.

[47] N. Hu, C. Guo, X. Dai et al., “Forsythiae fructuse water extract attenuates liver fibrosis via TLR4/MyD88/NF-κB and TGF-β/smads signaling pathways,” *Journal of Ethnopharmacology*, vol. 262, article 113275, 2020.

[48] M. Liu, Y. Xu, X. Han et al., “Dioscin alleviates alcoholic liver fibrosis by attenuating hepatic stellate cell activation via the TLR4/MyD88/NF-κB signaling pathway,” *Scientific Reports*, vol. 5, pp. 1–13, 2015.

[49] P. Behzadi and M. Gajdacs, “Writing a strong scientific paper in medicine and the biomedical sciences: a checklist and recommendations for early career researchers,” *Biologia Futura*, vol. 72, no. 4, pp. 395–407, 2021.